NCT01522547

Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease

A Prospective, Multi-Center, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety and Effect on Induction of Fetal Hemoglobin of CC-4047 In Subjects With Sickle Cell Disease

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Celgene · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine the maximum tolerated dose, safety and effect on induction of fetal hemoglobin of pomalidomide in patients with Sickle Cell Disease.

Conditions

• Anemia, Sickle Cell

Interventions

Type	Name	Description
DRUG	pomalidomide	Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg

Timeline

• Start date: 2007-08-01
• Primary completion: 2012-10-01
• Completion: 2013-12-01
• First posted: 2012-01-31
• Last updated: 2019-11-08

Locations

1 site across 1 country: United States